180 related articles for article (PubMed ID: 29721202)
1. Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.
Nanou A; Coumans FAW; van Dalum G; Zeune LL; Dolling D; Onstenk W; Crespo M; Fontes MS; Rescigno P; Fowler G; Flohr P; Brune C; Sleijfer S; de Bono JS; Terstappen LWMM
Oncotarget; 2018 Apr; 9(27):19283-19293. PubMed ID: 29721202
[TBL] [Abstract][Full Text] [Related]
2. Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients.
Isebia KT; Dathathri E; Verschoor N; Nanou A; De Jong AC; Coumans FAW; Terstappen LWMM; Kraan J; Martens JWM; Bansal R; Lolkema MP
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139564
[TBL] [Abstract][Full Text] [Related]
3. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM
Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900
[TBL] [Abstract][Full Text] [Related]
4. Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer.
Oeyen S; Liégeois V; De Laere B; Buys A; Strijbos M; Dirix P; Meijnders P; Vermeulen P; Van Laere S; Dirix L
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):499-506. PubMed ID: 33230201
[TBL] [Abstract][Full Text] [Related]
5. Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles.
Nanou A; Crespo M; Flohr P; De Bono JS; Terstappen LWMM
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30384500
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer.
Nanou A; Miao J; Coumans FAW; Dolce EM; Darga E; Barlow W; Smerage JB; Paoletti C; Godwin AK; Pusztai L; Sharma P; Thompson A; Hortobagyi GN; Terstappen LWMM; Hayes DF
JCO Precis Oncol; 2023 Jan; 7():e2200372. PubMed ID: 36634296
[TBL] [Abstract][Full Text] [Related]
7. Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival.
Nanou A; Miller MC; Zeune LL; de Wit S; Punt CJA; Groen HJM; Hayes DF; de Bono JS; Terstappen LWMM
Br J Cancer; 2020 Mar; 122(6):801-811. PubMed ID: 31937922
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer.
Zavridou M; Strati A; Bournakis E; Smilkou S; Tserpeli V; Lianidou E
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33668490
[TBL] [Abstract][Full Text] [Related]
9. Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer.
Nanou A; Mol L; Coumans FAW; Koopman M; Punt CJA; Terstappen LWMM
Cells; 2020 Dec; 9(12):. PubMed ID: 33333805
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
11. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
Strati A; Zavridou M; Bournakis E; Mastoraki S; Lianidou E
Analyst; 2019 Nov; 144(22):6671-6680. PubMed ID: 31596277
[TBL] [Abstract][Full Text] [Related]
12. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
13. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.
Yang YJ; Kong YY; Li GX; Wang Y; Ye DW; Dai B
BJU Int; 2019 Aug; 124(2):258-267. PubMed ID: 30536520
[TBL] [Abstract][Full Text] [Related]
14. Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study.
Zapatero A; Gómez-Caamaño A; Cabeza Rodriguez MÁ; Muinelo-Romay L; Martin de Vidales C; Abalo A; Calvo Crespo P; Leon Mateos L; Olivier C; Vega Piris LV
Radiat Oncol; 2020 Jun; 15(1):137. PubMed ID: 32487218
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.
Goodman OB; Fink LM; Symanowski JT; Wong B; Grobaski B; Pomerantz D; Ma Y; Ward DC; Vogelzang NJ
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1904-13. PubMed ID: 19505924
[TBL] [Abstract][Full Text] [Related]
16. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
18. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.
Helo P; Cronin AM; Danila DC; Wenske S; Gonzalez-Espinoza R; Anand A; Koscuiszka M; Väänänen RM; Pettersson K; Chun FK; Steuber T; Huland H; Guillonneau BD; Eastham JA; Scardino PT; Fleisher M; Scher HI; Lilja H
Clin Chem; 2009 Apr; 55(4):765-73. PubMed ID: 19233911
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
de Bono JS; Scher HI; Montgomery RB; Parker C; Miller MC; Tissing H; Doyle GV; Terstappen LW; Pienta KJ; Raghavan D
Clin Cancer Res; 2008 Oct; 14(19):6302-9. PubMed ID: 18829513
[TBL] [Abstract][Full Text] [Related]
20. Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
Lorente D; Olmos D; Mateo J; Bianchini D; Seed G; Fleisher M; Danila DC; Flohr P; Crespo M; Figueiredo I; Miranda S; Baeten K; Molina A; Kheoh T; McCormack R; Terstappen LW; Scher HI; de Bono JS
Eur Urol; 2016 Dec; 70(6):985-992. PubMed ID: 27289566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
